Blog

ACHI Analyzes Trends in Naloxone Prescription in Response to Opioid Epidemic

September 3, 2020

Author

John Lyon
Strategic Communications Manager
501-526-2244
jlyon@achi.net

 

  • Subscribe for Updates

In response to the opioid epidemic, policies to expand access to the anti-overdose drug naloxone have emerged across the country, including in Arkansas, where licensed pharmacists became authorized to order, dispense, and administer naloxone to individuals without a prescription in 2017.

To gain insight into the trends and patterns of naloxone prescriptions in Arkansas, ACHI conducted an analysis of naloxone and opioid prescriptions for Medicaid and commercially insured beneficiaries from state fiscal year (FY) 2017 to FY 2019, using data from the Arkansas All-Payer Claims Database, part of the Arkansas Healthcare Transparency Initiative. The results of our analysis are contained in our new data brief, Naloxone Prescription in Response to the Opioid Epidemic.

Key findings:

  • Among Medicaid and commercially insured beneficiaries, the number of individuals receiving opioid prescriptions decreased from FY 2017 to FY 2019, while the number of individuals receiving naloxone prescriptions increased.
  • The percentage of individuals who received both naloxone and high-dose opioid prescriptions (≥ 50 morphine milligram equivalents, or MME, per day) increased each state fiscal year. However, by FY 2019 the percentage with ≥ 50 MME per day opioid prescriptions and the percentage with ≥ 90 MME per day opioid prescriptions both remained low at 2.93% and 5.35%, respectively.
  • In FY 2019, one naloxone prescription was dispensed for every 34 individuals with ≥ 50 MME per day opioid prescriptions, and one naloxone prescription was dispensed for every 19 individuals with ≥ 90 MME per day opioid prescriptions.
  • In FY 2019, pharmacists authorized 1,130 out of 3,137 naloxone prescriptions under state protocol.

 

Some of our findings are also presented in two new infographics. See them here and here.